

Pharmaceutical Management Agency

Section H Update for Hospital Pharmaceuticals

Effective 1 May 2016

Cumulative for April and May 2016



Contents

Summary of decisions effective 1 May 2016	3
Section H changes to Part II	5
Index	11

Summary of decisions

EFFECTIVE 1 MAY 2016

- Amoxicillin with clavulanic acid (Augmentin) tab 500 mg with clavulanic acid 125 mg – addition of HSS
- Amoxicillin with clavulanic acid (Curam Duo) tab 500 mg with clavulanic acid 125 mg – to be delisted 1 August 2016
- Apomorphine hydrochloride (Movapo) inj 10 mg per ml, 2 ml ampoule – new listing
- Bimatoprost (Bimatoprost Actavis) eye drops 0.03%, 3 ml – new listing and addition of HSS
- Buspirone hydrochloride (Orion) tab 5 mg and 10 mg – new listing and addition of HSS
- Buspirone hydrochloride (Pacific Buspirone) tab 5 mg and 10 mg – to be delisted 1 July 2016
- Chloramphenicol (Chlorsig) eye oint 1%, 4 g – price decrease and addition of HSS
- Cinacalcet (Sensipar) tab 30 mg – new listing
- Dimercaptosuccinic acid (e.g. Pharmaceutical Compounding NZ) cap 200 mg – new presentation
- Dimercaptosuccinic acid (e.g. Pharmaceutical Compounding NZ) cap 100 mg – addition of example brand
- Fat modified feed (e.g. Monogen) powder 12.9 g protein, 69.1 g carbohydrate and 12.9 g fat per 100 g, 400 g can – new listing
- Galsulfase (Naglazyme) inj 1 mg per ml, 5 ml vial – new listing and addition of HSS
- Gentamicin sulphate (Pfizer) inj 40 mg per ml, 2 ml ampoule, 50 inj pack size – additional pack size listed
- High fat formula (Ketocal 4:1 (Unflavoured and Vanilla)) powder 14.4 g protein, 2.9 g carbohydrate and 69.2 g fat per 100 g, can – amended presentation description
- Intra-uterine device (Choice Load 375) IUD 35.5 mm length x 19.6 mm width – new listing
- Isopropyl alcohol (PSM) soln 70%, 500 ml, 1 and 12 bottle packs – to be delisted 1 July 2016
- Metoprolol succinate (Metoprolol – AFT CR) tab long-acting 23.75 mg, 47.5 mg, 95 mg and 190 mg, 30 tab pack – price decrease
- Milrinone (Milrinone Generic Health) inj 1 mg per ml, 10 ml ampoule – new listing and addition of HSS

Summary of decisions – effective 1 May 2016 (continued)

- Pegylated interferon alfa-2A inj 135 mcg prefilled syringe, and inj 135 mcg prefilled syringe (4) with ribavirin tab 200 mg (112) – to be delisted 1 July 2016
- Phentolamine mesylate inj 5 mg per ml, 1 ml ampule – new presentation listing

	Price (ex man. Excl. GST)	Brand or Generic Manufacturer
	\$	Per

Section H changes to Part II

Effective 1 May 2016

ALIMENTARY TRACT AND METABOLISM

- 20 GALSULFASE
 ➔ Inj 1 mg per ml, 5 ml vial – **1% DV May-16 to 2018** 2,234.00 1 Naglazyme
- Restricted
 Initiation
 Metabolic physician
Re-assessment required after 12 months
 Both:
 1 The patient has diagnosis of mucopolysaccharidosis VI; and
 2 Either:
 2.1 Diagnosis confirmed by demonstration of N-acetyl galactosamine-4-sulfatase (arylsulfatase B) deficiency confirmed by either an enzyme activity assay in leukocytes or skin fibroblasts; or
 2.2 Detection of two disease causing mutations and patient has a sibling who is known to have mucopolysaccharidosis VI.
- Continuation
 Metabolic physician
Re-assessment required after 12 months
 All of the following:
 1. The treatment remains appropriate for the patient and the patient is benefiting from treatment; and
 2. Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates; and
 3. Patient has not developed another life threatening or severe disease where the long term prognosis is unlikely to be influenced by Enzyme Replacement Therapy (ERT); and
 4. Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT.

CARDIOVASCULAR SYSTEM

- 40 PHENTOLAMINE MESYLATE (new presentation)
 Inj 5 mg per ml, 1 ml ampoule
- 42 METOPROLOL SUCCINATE (↓ price)
 Tab long-acting 23.75 mg 0.80 30 Metoprolol - AFT CR
 Tab long-acting 47.5 mg 1.16 30 Metoprolol - AFT CR
 Tab long-acting 95 mg 1.91 30 Metoprolol - AFT CR
 Tab long-acting 190 mg 3.85 30 Metoprolol - AFT CR
 Note – Metoprolol – AFT CR tab long-acting, all strengths of the 30 tab pack size, to be delisted from 1 June 2016.
- 48 MILRINONE (new listing and addition of HSS)
 Inj 1 mg per ml, 10 ml ampoule – **1% DV Jul-16 to 2018** 300.30 10 Milrinone Generic Health

GENITO-URINARY SYSTEM

- 57 INTRA-UTERINE DEVICE (new listing)
 IUD 35.5 mm length × 19.6 mm width 31.60 1 Choice Load 375

		Price (ex man. Excl. GST)	\$	Per	Brand or Generic Manufacturer
--	--	------------------------------	----	-----	-------------------------------------

Changes to Section H Part II – effective 1 May 2016 (continued)

HORMONE PREPARATIONS

- 61 CINACALCET (new listing)
 ➔ Tab 30 mg 403.70 28 Sensipar
 Restricted
 Initiation
 Nephrologist or endocrinologist
Re-assessment required after 6 months
 Either:
 1 All of the following:
 1.1 The patient has been diagnosed with a parathyroid carcinoma (see Note); and
 1.2 The patient has persistent hypercalcaemia (serum calcium ≥ 3 mmol/L) despite previous first-line treatments including bisphosphonates and sodium thiosulfate; and
 1.3 The patient is symptomatic; or
 2 All of the following:
 2.1 The patient has been diagnosed with calciphylaxis (calcific uraemic arteriolopathy); and
 2.2 The patient has symptomatic (e.g. painful skin ulcers) hypercalcaemia (serum calcium ≥ 3 mmol/L); and
 2.3 The patient's condition has not responded to previous first-line treatments including bisphosphonates and sodium thiosulfate.
 Continuation
 Nephrologist or endocrinologist
 Both:
 1 The patient's serum calcium level has fallen to < 3 mmol/L; and
 2 The patient has experienced clinically significant symptom improvement.
 Note: this does not include parathyroid adenomas unless these have become malignant.

INFECTIONS

- 71 GENTAMICIN SULPHATE (additional pack size)
 Inj 40 mg per ml, 2 ml ampoule – 1% DV Sep-15 to 2018 30.00 50 Pfizer
 74 AMOXICILLIN WITH CLAVULANIC ACID (addition of HSS)
 Tab 500 mg with clavulanic acid 125 mg
 – 1% DV Aug-16 to 2017 1.95 20 Augmentin
 Note – Curam Duo tab 500 mg with clavulanic acid 125 mg to be delisted from 1 August 2016.
 93 PEGYLATED INTERFERON ALFA-2A (delisting)
 Inj 135 mcg prefilled syringe
 Inj 135 mcg prefilled syringe (4) with ribavirin tab 200 mg (112)
 Note – Pegylated interferon alfa-2a inj 135 mcg prefilled syringe, and inj 135 mcg prefilled syringe (4) with ribavirin tab 200 mg (112) to be delisted from 1 July 2016

NERVOUS SYSTEM

- 105 APOMORPHINE HYDROCHLORIDE (new listing)
 Inj 10 mg per ml, 2 ml ampoule 119.00 5 Movapo



(Brand) indicates a brand example only. It is not a contracted product.

		Price (ex man. Excl. GST)	Brand or Generic Manufacturer
		\$	Per

Changes to Section H Part II – effective 1 May 2016 (continued)

124	BUSPIRONE HYDROCHLORIDE (new listing and addition of HSS) Tab 5 mg – 1% DV Jul-16 to 2018	23.80	100	Orion
	Tab 10 mg – 1% DV Jul-16 to 2018	14.96	100	Orion

Note – Pacific Buspirone tab 5 mg and 10 mg to be delisted from 1 July 2016.

SENSORY ORGANS

183	CHLORAMPHENICOL (↓ price and addition of HSS) Eye oint 1% – 1% DV Jul-16 to 2019	2.48	4 g	Chlorsig
187	BIMATOPROST (new listing and addition of HSS) Eye drops 0.03% – 1% DV Jul-16 to 2018	3.65	3 ml	Bimatoprost Actavis

VARIOUS

190	DIMERCAPTOSUCCINIC ACID (addition of example brand) Cap 100 mg.....		e.g. Pharmaceutical Compounding NZ	
190	DIMERCAPTOSUCCINIC ACID (new presentation) Cap 200 mg.....		e.g. Pharmaceutical Compounding NZ	
191	ISOPROPYL ALCOHOL (delisting) Soln 70%, 500 ml.....	5.00 60.00	1 12	PSM PSM

Note – PSM isopropyl alcohol soln 70%, 500 ml, 1 bottle and 12 bottle packs, to be delisted from 1 July 2016.

SPECIAL FOODS

206	FAT-MODIFIED FEED (new listing) Powder 12.9 g protein, 69.1 g carbohydrate and 12.9 g fat per 100 g, 400 g can		e.g. Monogen
210	HIGH FAT FORMULA (amended presentation description) Powder 14.4 g 15.25 g protein, 2.9 g 3 g carbohydrate and 69.2 g 73 g fat per 100 g, can.....	35.50	300 g

Ketocal 4:1 (Unflavoured)
Ketocal 4:1 (Vanilla)

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 April 2016

ALIMENTARY TRACT AND METABOLISM

15	MISOPROSTOL (new listing and addition of HSS) Tab 200 mcg – 1% DV Jun-16 to 2019	41.50	120	Cytotec
16	OMEPRAZOLE (↑ price) Inj 40 mg ampoule with diluent	33.65	5	Dr Reddy's Omeprazole

CARDIOVASCULAR SYSTEM

41	DIGOXIN (new listing and addition of HSS) Tab 62.5 mcg – 1% DV Jun-16 to 2019	6.67	240	Lanoxin PG
	Tab 250 mcg – 1% DV Jun-16 to 2019	14.52	240	Lanoxin
42	METOPROLOL SUCCINATE Tab long-acting 190 mg – 1% DV Jun-16 to 2018	11.54	90	Metoprolol - AFT CR
	Note – Metoprolol – AFT CR tab long-acting 190 mg, 30 tab pack, to be delisted from 1 June 2016.			
44	FUROSEMIDE [FRUSEMIDE] (↓ price and addition of HSS) Inj 10 mg per ml, 2 ml ampoule – 1% DV Jun-16 to 2019	1.20	5	Frusemide-Claris
44	PERHEXILINE MALEATE (addition of HSS) Tab 100 mg – 1% DV Jun-16 to 2019	62.90	100	Pexsig
47	ISOSORBIDE MONONITRATE (addition of HSS) Tab long-acting 40 mg – 1% DV Jun-16 to 2019	7.50	30	Ismo 40 Retard

GENITO-URINARY SYSTEM

59	DINOPROSTONE (amended presentation description) Vaginal gel 1 mg in 3 g 2.5-ml	52.65	1	Prostin E2
	Vaginal gel 2 mg in 3 g 2.5-ml	64.60	1	Prostin E2

HORMONE PREPARATIONS

69	DESMOPRESSIN ACETATE (↓ price and addition of HSS) → Tab 100 mcg – 1% DV Jun-16 to 2019	25.00	30	Minirin
	→ Tab 200 mcg – 1% DV Jun-16 to 2019	54.45	30	Minirin

INFECTIONS

73	CLARITHROMYCIN → Grans for oral liq 50 mg per ml	23.12	50 ml	Klacid
	Note – Klacid grans for oral liq 25 mg per ml, 70 ml to be delisted from 1 October 2016.			

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 April 2016 (continued)

MUSCULOSKELETAL SYSTEM

95	LEFLUNOMIDE (delisting)			
	Tab 100 mg	54.44	3	Arava
Note – Arava tab 100 mg to be delisted from 1 April 2016.				
102	CLOSTRIDIUM BOTULINUM TYPE A TOXIN			
	Inj 300 u vial	388.50	1	Dysport

NERVOUS SYSTEM

107	PROPOFOL (↓ price addition of HSS)			
	Inj 10 mg per ml, 20 ml vial – 10% DV Jun-16 to 2019	5.27	5	Provive MCT-LCT 1%
Note – Fresofol 1% inj 10 mg per ml, 20 ml ampoule, 50 ml vial and 100 ml vial to be delisted from 1 June 2016.				
107	PROPOFOL (new listing)			
	Inj 10 mg per ml, 50 ml vial – 10% DV Jun-16 to 2019	24.50	10	Fresofol 1% MCT/LCT
	Inj 10 mg per ml, 100 ml vial – 10% DV Jun-16 to 2019	49.00	10	Fresofol 1% MCT/LCT
107	PROPOFOL (delisting)			
	Inj 10 mg per ml, 20 ml ampoule	7.60	5	Fresofol 1%
	Inj 10 mg per ml, 20 ml vial	42.00	5	Diprivan
	Inj 10 mg per ml, 50 ml syringe	47.00	1	Diprivan
	Inj 10 mg per ml, 50 ml vial	4.00	1	Fresofol 1%
		25.00		Provive MCT-LCT 1%
	Inj 10 mg per ml, 100 ml vial	7.60	1	Diprivan
				Fresofol 1%
				Provive MCT-LCT 1%
Note – Fresofol 1% inj 10 mg per ml, 20 ml ampoule, 50 ml vial and 100 ml vial to be delisted from 1 June 2016.				
Note – Diprivan inj 10 mg per ml, 20 ml vial, 50 ml syringe, and 50 ml vial to be delisted from 1 June 2016.				
Note – Provive MCT-LCT 1% inj 10 mg per ml, 50 ml vial, 1 inj pack size and 100 ml vial, 1 inj pack size, to be delisted from 1 June 2016.				
108	BUPIVACAINE HYDROCHLORIDE WITH FENTANYL			
	Inj 0.625 mg with fentanyl 2 mcg per ml, 200 ml bag			
123	FLUPHENAZINE DECANOATE			
	Inj 25 mg per ml, 2 ml ampoule			<i>e.g. Modecate</i>

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

137	OXALIPLATIN (HSS suspended)			
	Inj 5 mg per ml, 10 ml vial			
	– 1% DV Mar-16 to 2018 31/3/16	13.32	1	Oxaliccord
Note – HSS for Oxaliccord inj 5 mg per ml, 10 ml and 20 ml vials has been suspended and will be reinstated from 1 June 2016 until 30 June 2018.				
	Inj 5 mg per ml, 20 ml vial			
	– 1% DV Mar-16 to 2018 31/3/16	16.00	1	Oxaliccord

	Price (ex man. Excl. GST)	\$	Per	Brand or Generic Manufacturer
--	------------------------------	----	-----	-------------------------------------

Changes to Section H Part II – effective 1 April 2016 (continued)

RESPIRATORY SYSTEM AND ALLERGIES

- 176 BEE VENOM (new listing)
 ➔ Maintenance kit - 6 vials 120 mcg freeze dried venom, with diluent
- 176 PAPER WASP VENOM (new listing)
 ➔ Treatment kit – 6 vials 120 mcg freeze dried venom, with diluent
- 176 YELLOW JACKET WASP VENOM (new listing)
 ➔ Treatment kit – 6 vials 120 mcg freeze dried venom, with diluent

SENSORY ORGANS

- 188 POLY/VINYL ALCOHOL (↓ price and addition of HSS)
 Eye drops 1.4% – 1% DV Jun-16 to 2019 2.62 15 ml **Vistil**
 Eye drops 3% – 1% DV Jun-16 to 2019 3.68 15 ml **Vistil Forte**
 Note – Liquifilm Tears eye drops 1.4% and Liquifilm Forte eye drops 3% to be delisted from 1 June 2016.

VARIOUS

- 192 IODISED OIL (↑ price)
 Inj 38% w/w (480 mg per ml), 10 ml ampoule 191.00 1 Lipiodol Ultra Fluid

SPECIAL FOODS

- 205 AMINO ACID ORAL FEED (new listing)
 ➔ Powder 11 g protein, 62 g carbohydrate
 and 1 g fat per sachet 4.50 80 g Vivonex TEN
- 205 AMINO ACID ORAL FEED (delisting)
 ➔ Powder 11.5 g protein, 61.7 g carbohydrate
 and 0.8 g fat per sachet 4.50 80.4 g Vivonex TEN
 Note – Vivonex TEN powder, 80.4 g pack size, to be delisted from 1 June 2016.
- 213 ENTERAL FEED 1 KCAL/ML
 ➔ Liquid 4 g protein, 13.6 g carbohydrate
 and 3.4 g fat per 100 ml, bottle 2.65 500 ml Osmolite RTH
 ➔ Liquid 4 g protein, 13.6 g carbohydrate
 and 3.4 g fat per 100 ml, can 1.24 250 ml Osmolite
 Note – Osmolite RTH 500 ml and Osmolite 250 ml to be delisted from 1 June 2016.

Index

Pharmaceuticals and brands

A	
Amino acid oral feed	10
Amoxicillin with clavulanic acid	6
Apomorphine hydrochloride	6
Arava	9
Augmentin	6
B	
Bee venom.....	10
Bimatoprost	7
Bimatoprost Actavis	7
Bupivacaine hydrochloride with fentanyl	9
Buspirone hydrochloride.....	7
C	
Chloramphenicol.....	7
Chlorsig	7
Choice Load 375.....	5
Cinacalcet.....	6
Clarithromycin.....	8
Clostridium botulinum type a toxin.....	9
Cytotec	8
D	
Desmopressin acetate.....	8
Digoxin	8
Dimercaptosuccinic acid	7
Dinoprostone	8
Diprivan	9
Dr Reddy's Omeprazole.....	8
Dysport.....	9
E	
Enteral feed 1 kcal/ml.....	10
F	
Fat-modified feed	7
Fluphenazine decanoate	9
Fresofol 1%.....	9
Fresofol 1% MCT/LCT	9
Frusemide	8
Frusemide-Claris.....	8
Furosemide	8
G	
Galsulfase.....	5
Gentamicin sulphate.....	6
H	
High fat formula	7
I	
Intra-uterine device.....	5
Iodised oil	10
Ismo 40 Retard	8
Isopropyl alcohol.....	7
Isosorbide mononitrate	8
K	
Ketocal 4:1 (Unflavoured).....	7
Ketocal 4:1 (Vanilla).....	7
Klacid	8
L	
Lanoxin.....	8
Lanoxin PG	8
Leflunomide	9
Lipiodol Ultra Fluid	10
M	
Metoprolol - AFT CR.....	5, 8
Metoprolol succinate	5, 8
Milrinone	5
Milrinone Generic Health.....	5
Minirin	8
Misoprostol.....	8
Modecate.....	9
Movapo	6
N	
Naglazyme	5
O	
Omeprazole	8
Osmolite	10
Osmolite RTH.....	10
Oxaliccord.....	9
Oxaliplatin	9
P	
Paper wasp venom	10
Pegylated interferon alfa-2a.....	6
Perhexiline maleate	8
Pexsig.....	8
Phentolamine mesylate	5
Polyvinyl alcohol	10
Propofol	9
Prostin E2	8
Provive MCT-LCT 1%	9
S	
Sensipar	6
V	
Vistil	10
Vistil Forte.....	10
Vivonex TEN.....	10
Y	
Yellow jacket wasp venom	10



Email: enquiry@pharmac.govt.nz
www.pharmac.govt.nz/medicines/hospital-pharmaceuticals

Pharmaceutical Management Agency
Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand
Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz

ISSN 1172-3694 (Print) - ISSN 1179-3708 (Online)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.